يعرض 1 - 20 نتائج من 48 نتيجة بحث عن '"мелфалан"', وقت الاستعلام: 0.51s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal

    المصدر: Acta Biomedica Scientifica; Том 7, № 2 (2022); 12-23 ; 2587-9596 ; 2541-9420

    وصف الملف: application/pdf

    Relation: https://www.actabiomedica.ru/jour/article/view/3408/2320; WHO Coronavirus (COVID-19) Dashboard. URL: https://covid19.who.int [date of access: 03.03.2022].; Szmigiera M. Impact of the coronavirus pandemic on the global economy – Statistics & Facts. URL: https://www.statista.com/topics/6139/covid-19-impact-on-the-global-economy [date of access: 03.03.2022].; Временные методические рекомендации Минздрава России «Профилактика, диагностика и лечение коронавирусной инфекции (COVID-19)», версия 15 от 22.02.2022. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/059/392/original/%D0%92%D0%9C%D0%A0_COVID-19_V15.pdf [дата доступа: 03.03.2022].; Calderón-Parra J, Múñez-Rubio E, Fernández-Cruz A, García Sánchez MC, Maderuelo-González E, López-Dosil M, et al. Incidence, clinical presentation, relapses and outcome of SARSCoV-2 infection in patients treated with anti-CD20 monoclonal antibodies. Clin Infect Dis. 2021; ciab700. doi:10.1093/cid/ciab700; Salesi M, Shojaie B, Farajzadegan Z, Salesi N, Mohammadi E. TNF-α blockers showed prophylactic effects in preventing COVID-19 in patients with rheumatoid arthritis and seronegative spondyloarthropathies: A case-control study. Rheumatol Ther. 2021; 8(3): 1355-1370. doi:10.1007/s40744-021-00342-8; Duarte MBO, Leal F, Argenton JLP, Carvalheira JBC. Outcomes of COVID-19 patients under cytotoxic cancer chemotherapy in Brazil. Cancers (Basel). 2020; 12(12): 3490. doi:10.3390/cancers12123490; Цветов В.М., Бурашникова И.С., Сычев Д.А., Поддубная И.В. Возможность и перспективы применения препаратов из группы цитостатиков у пациентов с COVID-19 на примере циклофосфамида. Фарматека. 2021; 28(1): 10-13. doi:10.18565/pharmateca.2021.1.10-13; Revannasiddaiah S, Devadas SK, Palassery R, Pant NK, Maka VV. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2. Med Hypotheses. 2020; 144: 109850. doi:10.1016/j.mehy.2020.109850; Pukhalsky AL, Shmarina GV. Stimulatory and protective effects of alkylating agent applied in ultra-low concentrations. Pharmacology. 2000; 62(3): 129-132. doi:10.1159/000056084; Пухальский А.Л., Шмарина Г.В., Алёшкин В.А. Ультранизкие дозы мелфалана снижают тяжесть экспериментального колита у мышей. Бюллетень экспериментальной биологии и медицины. 2006; 142(10): 418-422.; Pukhalsky A, Toptygina A, Khaudukov S. Interleukin-2 receptor β chain as a possible target for low doses of mafosfamide. Mediators Inflamm. 1995; 4(3): 175-180. doi:10.1155/S0962935195000287; Pukhalsky AL, Shmarina GV, Alioshkin V, Sabelnikov A. Alkylating drugs applied in non-cytotoxic doses as a novel compounds targeting inflammatory signal pathway. Biochem Pharmacol. 2006; 72(11): 1432-1438. doi:10.1016/j.bcp.2006.03.008; Соколов Е.И., Пухальский А.Л., Зыков К.А., Шмарина Г.В., Матько Л.Ю., Демидов Ю.И. и др. Иммуномодулирующие эффекты ингаляций ультра низких доз алкилирующего цитостатика мелфалана у больных бронхиальной астмой. Пульмонология. 2002; 5: 81-86.; Pukhalsky A, Zykov K. Ultra-low doses of Melphalan in the treatment of patients with severe asthma: Basis of new approach. 3rd Congress of European Region International Union against Tuberculosis and Lung Diseases (IUATLD) Suppl. Book. 2004: 206.; Временные методические рекомендации Минздрава России «Профилактика, диагностика и лечение коронавирусной инфекции (COVID-19)», версия 6 от 28.04.2020. URL: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/116/original/28042020_%D0%9CR_COVID-19_v6.pdf [дата доступа: 03.03.2022].; Временные методические рекомендации Минздрава России «Профилактика, диагностика и лечение коронавирусной инфекции (COVID-19)», версия 7 от 03.06.2020. URL: http://edu.rosminzdrav.ru/fileadmin/user_upload/specialists/COVID-19/MR_COVID-19_v7.pdf [дата доступа: 03.03.2022].; Временные методические рекомендации Минздра-ва России «Профилактика, диагностика и лечение коронавирусной инфекции (COVID-19)», версия 8 от 03.09.2020. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v8.pdf [дата доступа: 03.03.2022].; Временные методические рекомендации Минздрава России «Профилактика, диагностика и лечение коронавирусной инфекции (COVID-19)», версия 9 от 26.10.2020. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf [дата доступа: 03.03.2022].; Зыков К.А. Клинико-иммунологические и морфологические изменения при терапии бронхиальной астмы иммунодепрессивными препаратами: дисс. … д-ра мед. наук. М.; 2009.; https://www.actabiomedica.ru/jour/article/view/3408

  3. 3
    Academic Journal

    المصدر: Research and Practical Medicine Journal; Том 8, № 4 (2021); 80-86 ; Research'n Practical Medicine Journal; Том 8, № 4 (2021); 80-86 ; 2410-1893 ; 10.17709/2410-1893-2021-8-4

    وصف الملف: application/pdf

    Relation: https://www.rpmj.ru/rpmj/article/view/755/465; https://www.rpmj.ru/rpmj/article/downloadSuppFile/755/578; https://www.rpmj.ru/rpmj/article/downloadSuppFile/755/579; Cohen VML, Carter MJ, Kemeny A, Radatz M, Rennie IG. Metastasis-free survival following treatment for uveal melanoma with either stereotactic radiosurgery or enucleation. Acta Ophthalmol Scand. 2003 Aug;81(4):383-388. https://doi.org/10.1034/j.1600-0420.2003.00101.x; Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-4659. https://doi.org/10.1167/iovs.03-0538; McLaughlin CC, Wu X-C, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. Cancer. 2005 Mar 1;103(5):1000-1007. https://doi.org/10.1002/cncr.20866; Alexander HR, Libutti SK, Pingpank JF, Steinberg SM, Bartlett DL, Helsabeck C, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003 Dec 15;9(17):6343-6349.; Noter SL, Rothbarth J, Pijl MEJ, Keunen JEE, Hartgrink HH, Tijl FGJ, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res. 2004 Feb;14(1):67-72. https://doi.org/10.1097/00008390-200402000-00011; Van Iersel LBJ, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FGJ, Putter H, et al. Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol. 2008 Jun;19(6):1127-1134. https://doi.org/10.1093/annonc/mdn032; Fiorentini G, Aliberti C, Del Conte A, Tilli M, Rossi S, Ballardini P, et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo. 2009 Feb;23(1):131-137.; https://www.rpmj.ru/rpmj/article/view/755

  4. 4
    Academic Journal

    المصدر: Meditsinskiy sovet = Medical Council; № 20 (2021); 117-123 ; Медицинский Совет; № 20 (2021); 117-123 ; 2658-5790 ; 2079-701X

    وصف الملف: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/6588/5971; Egan K.M., Seddon J.M., Glynn R.J., Gragoudas E.S., Albert D.M. Epidemiologic aspects of uveal melanoma. Surv Ophthalmol. 1988;32(4):239–251. https://doi.org/10.1016/0039-6257(88)90173-7.; Kincaid M.C. Uveal melanoma. Cancer Control. 1998;5(4):299–309. https://doi.org/10.1177/107327489800500401.; Seregard S. Posterior uveal melanoma. The Swedish perspective. Acta Ophthalmol Scand. 1996;74(4):315–329. https://doi.org/10.1111/j.1600-0420.1996.tb00701.x.; The collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS). JAMA Ophthalmol. 2001;119(5):670–676. https://doi.org/10.1001/archopht.119.5.670.; Folberg R. Tumor progression in ocular melanomas. J Invest Dermatol. 1993;100(3):3265–3315. Available at: https://pubmed.ncbi.nlm.nih.gov/8440916/.; Shields J.A., Shields C.L., Donoso L.A. Management of posterior uveal melanoma. Surv Ophthalmol. 1991;36(3):161–195. https://doi.org/10.1016/0039-6257(91)90001-v.; Gragoudas E.S., Egan K.M., Seddon J.M., Glynn R.J., Walsh S.M., Finn S.M. et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98(3):383–389. https://doi.org/10.1016/s0161-6420(91)32285-1.; Kath R., Hayungs J., Bornfeld N., Sauerwein W., Hoffken K., Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72(7):2219–2223. https://doi.org/10.1002/1097-0142(19931001)72:73.0.co;2-j.; Rajpal S., Moore R., Karakousis C.P. Survival in metastatic ocular melanoma. Cancer. 1983;52(2):334–336. https://doi.org/10.1002/1097-0142(19830715)52:23.0.co;2-e.; Eskelin S., Pyrhonen S., Hahka-Kemppinen M., Tuomaala S., Kivela T. A prognostic model and staging for metastatic uveal melanoma. Cancer. 2003;97(2):465–475. https://doi.org/10.1002/cncr.11113.; Alexander H.R., Libutti S.K., Pingpank J.F., Steinberg S.M., Bartlett D.L., Helsabeck C., Beresneva T. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9(17):6343–6349. Available at: https://pubmed.ncbi.nlm.nih.gov/14695133/.; Olofsson R., Ny L., Eilard M.S., Rizell M., Cahlin C., Stierner U. et al. Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases (the SCANDIUM trial): study protocol for a randomized controlled trial. Trials. 2014;15:317. https://doi.org/10.1186/1745-6215-15-317.; Alexander H.R., Libutti S.K., Bartlett D.L., Puhlmann M., Fraker D.L., Bachenheimer L.C. A phase I–II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6(8):3062–3070. Available at: https://clincancerres.aacrjournals.org/content/6/8/3062.long.; Alexander H.R., Bartlett D.L., Libutti S.K., Fraker D.L., Moser T., Rosenberg S.A. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16(4):1479–1489. https://doi.org/10.1200/JCO.1998.16.4.1479.; Bates D.A., Mackillop W.J. The effect of hyperthermia in combination with melphalan on drug-sensitive and drug-resistant CHO cells in vitro. Br J Cancer. 1990;62(2):183–188. https://doi.org/10.1038/bjc.1990.257.; van der Zee J., Kroon B.B., Nieweg O.E., van de Merwe S.A., Kampinga H.H. Rationale for different approaches to combined melphalan and hyperthermia in regional isolated perfusion. Eur J Cancer. 1997;33(10):1546–1550. https://doi.org/10.1016/s0959-8049(97)00116-0.; Hafstrom L.R., Holmberg S.B., Naredi P.L., Lindner P.G., Bengtsson A., Tidebrant G., Schersten T.S. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol. 1994;3(2):103–108. https://doi.org/10.1016/0960-7404(94)90005-1.; Rothbarth J., Pijl M.E.J., Vahrmeijer A.L., Hartgrink H.H., Tijl F.G.J, Kuppen P.J.K. et al. Isolated hepatic perfusion with high dose melphalan for the treatment of metastatic colorectal cancer confined to the liver. Br J Surg. 2003;90(11):1391–1397. https://doi.org/10.1002/bjs.4308.; Vahrmeijer A.L., van Dierendonck J.H., Keizer H.J., Beijnen J.H., Tollenaar R.A., Pijl M.E. et al. Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer. 2000;82(9):1539–1546. https://doi.org/10.1054/bjoc.2000.1175.; Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–214. https://doi.org/10.1002/1097-0142(19810101)47:13.0.co;2-6.; Aoyama T., Mastrangelo M.J., Berd D., Nathan F.E., Shields C.L., Shields J.A. et al. Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000;89(7):1561–1568. https://doi.org/10.1002/1097-0142(20001001)89:73.0.co;2-r.; Bedikian A.Y., Legha S.S., Mavligit G., Carrasco C.H., Khorana S., Plager C. et al. Treatment of uveal melanoma metastatic to the liver: a review of the M.D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76(9):1665–1670. https://doi.org/10.1002/1097-0142(19951101)76:93.0.co;2-j.; Becker J.C., Terheyden P., Kampgen E., Wagner S., Neumann C., Schadendorf D. et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer. 2002;87(8):840–845. https://doi.org/10.1038/sj.bjc.6600521.; Kivela T., Suciu S., Hansson J., Kruit W.H., Vuoristo M.S., Kloke O. et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer. 2003;39(8):1115–1120. https://doi.org/10.1016/s0959-8049(03)00132-1.; Nathan F.E., Berd D., Sato T., Shield J.A., Shields C.L., De Potter P. et al. BOLD + interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res. 1997;16(2):201–208. Available at: https://pubmed.ncbi.nlm.nih.gov/9261748/.; Pyrhonen S., Hahka-Kemppinen M., Muhonen T., Nikkanen V., Eskelin S., Summanen P. et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer. 2002;95(11):2366–2372. https://doi.org/10.1002/cncr.10996.; Egerer G., Lehnert T., Max R., Naeher H., Keilholz U., Ho A.D. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients. Int J Clin Oncol. 2001;6(1):25–28. https://doi.org/10.1007/pl00012075.; Leyvraz S., Spataro V., Bauer J., Pampallona S., Salmon R., Dorval T. et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol. 1997;15(7):2589–2595. https://doi.org/10.1200/JCO.1997.15.7.2589.; Mavligit G.M., Charnsangavej C., Carrasco C.H., Patt Y.Z., Benjamin R.S., Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. J Am Med Assoc. 1988;260(7):974–976. https://doi.org/10.1001/jama.1988.03410070102037.; Richardson P.G., Murakami C., Jin Z., Warren D., Momtaz P., Hoppensteadt D. et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002;100(13):4337–4343. https://doi.org/10.1182/blood-2002-04-1216.; Ben-Shabat I., Belgrano V., Ny L., Nilsson J., Lindner P., Olofsson Bagge R. Long-Term Follow-Up Evaluation of 68 Patients with Uveal Melanoma Liver Metastases Treated with Isolated Hepatic Perfusion. Ann Surg Oncol. 2016;23(4):1327–1234. https://doi.org/10.1245/s10434-015-4982-5.; Eggermont A.M., van Ijken M.G., van Etten B., van der Sijp J.R., ten Hagen T.L., Wiggers T., et al. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure. Hepatogastroenterology. 2000;47(33):776–781. Available at: https://pubmed.ncbi.nlm.nih.gov/10919031/.; van Ijken M.G., de Bruijn E.A., de Boeck G., ten Hagen T.L., van der Sijp J.R., Eggermont A.M. Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan, and mitomycin C using balloonatheter techniques: a pharmacokinetic study in pigs. Ann Surg. 1998;228(6):763–770. https://doi.org/10.1097/00000658-199812000-00007.; Rothbarth J., Pijl M.E.J., Tollenaar R.A.E.M., Tijl F., Ivancev G., Mulder G.J. et al. An experimental minimally invasive perfusion technique for the treatment of liver metastases. Eur J Surg Oncol. 2003;29(9):757–763. https://doi.org/10.1016/j.ejso.2003.08.004.; Vogl T.J., Koch S.A., Lotz G., Gebauer B., Willinek W., Engelke C. et al. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study. Cardiovasc Intervent Radiol. 2017;40(6):864–872. https://doi.org/10.1007/s00270-017-1588-2.; Carr M.J., Sun J., Cohen J.B., Liu J., Serdiuk A.A., Stewart S.R. et al. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases. Cancer Control. 2020;27(1):1073274820983019. https://doi.org/10.1177/1073274820983019.; https://www.med-sovet.pro/jour/article/view/6588

  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal
  9. 9
    Academic Journal

    المصدر: International Journal of Medicine and Medical Research; Vol. 5 No. 1 (2019): International Journal of Medicine and Medical Research; 66-74 ; International Journal of Medicine and Medical Research; Том 5 № 1 (2019): International Journal of Medicine and Medical Research; 66-74 ; 2414-9985 ; 2413-6077 ; 10.11603/ijmmr.2413-6077.2019.1

    وصف الملف: application/pdf

  10. 10
    Academic Journal

    المؤلفون: Shevchuk, O. O.

    المصدر: Achievements of Clinical and Experimental Medicine; No. 4 (2019); 161-166 ; Достижения клинической и экспериментальной медицины; № 4 (2019); 161-166 ; Здобутки клінічної і експериментальної медицини; № 4 (2019); 161-166 ; 2415-8836 ; 1811-2471 ; 10.11603/1811-2471.2019.v.i4

    وصف الملف: application/pdf

  11. 11
    Academic Journal

    المصدر: Клінічна та експериментальна патологія; Том 18 № 4 (2019) ; Клиническая и экспериментальная патология; Том 18 № 4 (2019) ; Clinical & experimental pathology; Vol. 18 No. 4 (2019) ; 1727-4338

    وصف الملف: application/pdf

  12. 12
    Academic Journal

    المصدر: Bulletin of Scientific Research; No 1 (2017) ; Вестник научных исследований; № 1 (2017) ; Вісник наукових досліджень; № 1 (2017) ; 2415-8798 ; 1681-276X ; 10.11603/2415-8798.2017.1

    وصف الملف: application/pdf

  13. 13
    Academic Journal

    المساهمون: The study was performed without external funding., Исследование проведено без спонсорской поддержки.

    المصدر: Russian Journal of Pediatric Hematology and Oncology; Том 6, № 1 (2019); 40-47 ; Российский журнал детской гематологии и онкологии (РЖДГиО); Том 6, № 1 (2019); 40-47 ; 2413-5496 ; 2311-1267 ; 10.21682/2311-1267-2019-6-1

    وصف الملف: application/pdf

    Relation: https://journal.nodgo.org/jour/article/view/470/451; Феденко А.А., Бохян А.Ю., Горбунова В.А., Махсон А.Н., Тепляков В.В. Практические рекомендации по лечению первичных злокачественных опухолей костей (остеосаркома, саркома Юинга). Злокачественные опухоли 2016;2(4):186–99. doi:10.18027 / 2224– 5057–2017–7–3s2–203–215.; Сенжапова Э.Р., Дзампаев А.З., Хестанов Д.Б., Нисиченко Д.В., Рыков М.Ю. Клинические рекомендации по диагностике и лечению детей с остеосаркомой. НМИЦ онкологии им. Н.Н. Блохина Минздрава России. Российское общество; детских онкологов, 2015. [Электронный ресурс]; http://www.pediatriconcology.ru/upload/iblock/ee6/osteosarkoma.pdf (дата обращения 19.08.18).; Meyers P.A., Schwartz C.L., Krailo M.D., Healey J.H., Bernstein M.L., Betcher D., Ferguson W.S., Gebhardt M.C., Goorin A.M., Harris M., Kleinerman E., Link M.P., Nadel H., Nieder M., Siegal G.P., Weiner M.A., Wells R.J., Womer R.B., Grier H.E.; Children’s Oncology Group. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survivala report from the Children’s Oncology Group. J Clin Oncol 2008;26:633–8. doi:10.1200/JCO.2008.14.0095.; Temeck B.K., Wexler L.H., Steinberg S.M., McClure L.L., Horowitz M., Pass H.I. Metastasectomy for sarcomatous pediatric histologies: results and prognostic factors. Ann Thorac Surg 1995;59(6):1385–9; discussion 1390. PMID: 7771815.; Kayton M.L. Pulmonary metastasectomy in pediatric patients. Thorac Surg Clin 2006;16:167–83. doi:10.1016/j.thorsurg.2006.01.001.; Fuchs J., Seitz G., Handgretinger R., Schafer J., Warmann S.W. Surgical treatment of lung metastases in patients with embryonal pediatric solid tumors: an update. Semin Pediatr Surg 2012;21(1):79–87. doi:10.1053/j.sempedsurg.2011.10.008.; Chou A.J., Kleinerman E.S., Krailo M.D., Chen Z., Betcher D.L., Healey J.H., Conrad E.U. 3rd, Nieder M.L., Weiner M.A., Wells R.J., Womer R.B., Meyers P.A.; Children’s Oncology Group. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer 2009;115:5339–48. doi:10.1002/cncr.24566.; Buddingh E.P., Anninga J.K., Versteegh M.I., Taminiau A.H., Egeler R.M., van Rijswijk C.S., Hogendoorn P.C., Lankester A.C., Gelderblom H. Prognostic factors in pulmonary metastasized highgrade osteosarcoma. Pediatr Blood Cancer 2010;54(22):216–21. doi:10.1002/pbc.22293.; Gelderblom H., Jinks R.C., Sydes M., Bramwell V.H., van Glabbeke M., Grimer R.J., Hogendoorn P.C., McTiernan A., Lewis I.J., Nooij M.A., Taminiau A.H., Whelan J. Survival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials. Eur J Cancer 2011;47:895–902. doi:10.1016/j.ejca.2010.11.036.; Briccoli A., Rocca M., Salone M., Guzzardella G.A., Balladelli A., Bacci G. High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985–2005. Surg Oncol 2010;19:193–9.; Slade A.D., Warneke C.L., Hughes D.P., Lally K.P., Hayes-Jordan A.A., Austin M.T. Effect of concurrent metastatic disease on survival in children and adolescents undergoing lung resection for metastatic osteosarcoma. J Pediatr Surg 2015;50:157–60; discussion 160.; Leary S.E., Wozniak A.W., Billups C.A., Wu J., McPherson V., Neel M.D., Rao B.N., Daw N.C. Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Children’s Research Hospital experience. Cancer 2013;119:2645–53. doi:10.1002/cncr.28111.; Harting M.T., Blakely M.L., Jaffe N., Cox C.S., Hayes-Jordan A., Benjamin R.S., Raymond A.K., Andrassy R.J., Lally K.P. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg 2006;41:194–9. doi:10.1016/j.jpedsurg.2005.10.089.; McCarville M.B., Kaste S.C., Cain A.M., Goloubeva O., Rao B.N., Pratt C.B. Prognostic factors and imaging patterns of recurrent pulmonary nodules after thoracotomy in children with osteosarcoma. Cancer 2001;91:1170–6. PMID: 11267963.; Heij H.A., Vos A., Kraker J., Voute P.A. Prognostic factors in surgery for pulmonary metastases in children Prognostic factors in surgery for pulmonary metastases in children. Surgery 1994;115:687–93. PMID: 8197559.; Paulussen M., Ahrens S., Craft A.W., Dunst J., Frohlich B., Jabar S., Rube C., Winkelmann W., Wissing S., Zoubek A., Jurgens H. Ewing’s tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing’s Sarcoma Studies patients. J Clin Oncol 1998;16:3044–52. doi:10.1200/JCO.1998.16.9.3044.; Letourneau P.A., Shackett B., Xiao L., Trent J., Lally K., Hayes-Jordan A. Resection of pulmonary metastases in pediatric patients with Ewing sarcoma improves survival. J Pediatr Surg 2011;46:332–5. doi:10.1016/j.jpedsurg.2010.11.013.; Hendriks J.M.H., Van Schil P., Van Oosterom A., Kuppen P.J.K., van Marck E., Eyskens E. Isolated lung perfusion with melphalan prolongs survival in a rat model of metastatic pulmonary adenocarcinoma. Eur Surg Res1999;31:267–71. doi:10.1159/000008702.; Schröder C., Fisher S., Pieck A., Muller A., Jaehde U., Kirchner H., Haverich A., Macchiarini P. Technique and results of hyperthermic isolated lung perfusion with high-doses of cisplatin for the treatment of surgically relapsing or unresectable lung sarcoma metastasis. Eur J Cardiothorac Surg 2002;22:41–6. doi:10.1016/S1010-7940(02)00216-6.; Van Schil P.E. Surgical treatment for pulmonary metastases. Acta Clin Belg 2002;57(6):333–9. doi:10.1179/acb.2002.062.; Nawata S., Abecasis N., Ross H.M., Abolhoda A., Cheng H., Sachar K.S., Burt M.E. Isolated lung perfusion with melphalan for the treatment of metastatic pulmonary sarcoma. J Thorac Cardiovasc Surg 1996;112(6):1542–7; discussion 1547–8.; Hendriks J.M.H., Van Schil P.E.Y. Isolated lung perfusion for; the treatment of pulmonary metastases. Surg Oncol 1998;7(1):59–63. doi:10.1016/S0960-7404(98)00028-0.; Левченко Е.В., Тимофеева Е.С., Сенчик К.Ю., Моисеенко В.М., Барчук А.С., Лемехов В.Г., Дунаевский И.В., Гельфонд В.М. Перфузия изолированного легкого цитостатиками. Первый опыт. Вопросы онкологии 2011;57(4):533.; Тимофеева Е.С., Левченко Е.В., Моисеенко В.М. Изолированная перфузия легкого цитостатиками. Вопросы онкологии 2011;57(2):147–54.; Левченко Е.В., Тимофеева Е.С., Сенчик К.Ю., Моисеенко В.М., Барчук А.С., Лемехов В.Г., Дунаевский И.В., Гельфонд В.М., Горохов Л.В. Изолированная химиоперфузия легкого цитостатиками. Опыт применения. Актуальные вопросы клинической онкологии. Сборник научных трудов, посвященный 65-летию Санкт-Петербургского государственного учреждения здравоохранения «Городской клинический онкологический диспансер» и 20-летию Санкт-Петербургской общественной организации «Ассоциация помощи онкологическим больным «Антирак» 2011:162–3.; Левченко Е.В., Калинин П.С., Сенчик К.Ю., Чжан Вэнь, Ван Тин, Мамонтов О.Ю., Мищенко А.В., Шевкунов Л.Н., Ульянченко Я.А., Левченко Н.Е., Гумбатова Э.Д., Дубинина Т.В. Обоснование модели расчета индивидуальной дозы цитостатиков с использованием КТ-волюметрии для изолированной химиоперфузии легкого с метастазэктомией. Вопросы онкологии 2018;64(3):319–23.; https://journal.nodgo.org/jour/article/view/470

  14. 14
    Academic Journal
  15. 15
    Academic Journal

    المؤلفون: Ю. Б. Белоусов

    المصدر: Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice; № 4 (2003); 11-23 ; Качественная клиническая практика; № 4 (2003); 11-23 ; 2618-8473 ; 2588-0519

    وصف الملف: application/pdf

  16. 16
  17. 17
    Academic Journal

    المصدر: Diagnostic radiology and radiotherapy; № 3 (2016); 40-45 ; Лучевая диагностика и терапия; № 3 (2016); 40-45 ; 2079-5343 ; 10.22328/2079-5343-2016-3

    وصف الملف: application/pdf

    Relation: https://radiag.bmoc-spb.ru/jour/article/view/149/150; Трахтенберг А. Х., Паршин В. Д., Пикин О. В. и др. Хирургическое лечение метастазов колоректального рака в легких // Росс. онкол. журнал.- 2005.- № 4.- С. 18-21.; Чиссов В. И., Трахтенберг А. Х., Пикин О. В. Метастатические опухоли легких.- М.: ГЭОТАР-Медиа, 2009.- 160 с.; Hendriks J. М., Grootenboers M. J., Schramel F. М. et al. Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial // Ann. Thorac. Surg.- 2004.- Vol. 78.- P 1919-1926.; Pastorino U., Buyse М., Friedel G. et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases // J. Thorac. Cardiovasc. Surg.- 1997.- Vol. 113.- P 37-49.; Van Schil P. E. Surgical treatment for pulmonary metastases // Acta. Clin. Belg.- 2002.- Vol. 57.- P. 333-339.; Van Schil P. E., Hendriks J. М., Van Putte B. Р Isolated lung perfusion and related techniques for the treatment of pulmonary metastases // J. Cardiothorac. Surg.- 2008.- Vol. 33.- P. 487-496.; Blackmon S. H., Stephens E. H., Correa A. M. et al. Predictors of recurrent pulmonary metastases and survival after pulmonary metastasectomy for colorectal cancer // Ann. Thorac. Surg.- 2012.- Vol. 6 (94).- P 1802-1809.; Hendriks J. M., Van Putte B. P., Grootenboers M. et al. Isolated lung perfusion for pulmonary metastases // Thorac. Surg. Clin.- 2006.- Vol. 16.- P. 185-198.; Takakura Y., Miyata Y., Okajima M. et al. Short disease-free interval is a significant risk factor for intrapulmonary recurrence after resection of pulmonary metastases in colorectal cancer // Colorectal Dis.- 2010.- Vol. 12.- P. 68-57.; Hendriks J. М., Romijn S., Van Putte B. et al. Long-term results of surgical resection of lung metastases // Acta. Chir. Belg.- 2001.- Vol. 101.- P. 267-272.; Hengst W. A., Hendriks J. М., Balduyck B. et al. Phase II Multicenter Clinical Trial of Pulmonary Metastasectomy and Isolated Lung Perfusion with Melphalan in Patients with Resectable Lung Metastases // Journal of Thoracic Oncology.- 2014.- Vol. 9.- P. 1547-553.; Ratto G. B., Toma S., Civalleri D. et al. Isolated lung perfusion with platinum in the treatment of pulmonary metastases from soft tissue sarcomas // J. Thorac. Cardiovasc. Surg.- 1996.- Vol. 112.- P. 614-622.; Ward A., Prokrym K., Pass H. Isolated Lung Perfusion for Pulmonary Metastases // Thoracic. Surgery Clinics.- 2016.- Vol. 26 (1).- P. 55-67.; Grootenboers M. J., Schramel F. M., Boven W. J. et al. Re-evaluation of toxicity and long-term follow-up of isolated lung perfusion with melphalan in patients with resectable pulmonary metastases: phase I and extentional trial // Ann. Thorac. Surg.- 2007.- Vol. 83.- P. 1235-1236.; Авдеев С. Н. Дыхательная недостаточность // Consilium Medicum.- 2004.- № 4.- С. 44-48.; Гиппи М. А. Патофизиология легких.- СПб.: Невский диалект, 1999.- 344 с.; Левченко Е. В., Сенчик К. Ю., Барчук А. С. и др. Изолированная химиоперфузия легкого по поводу метастазов солидных опухолей // Онкохирургия.- 2012.- Т. 4.- С. 46-53.; https://radiag.bmoc-spb.ru/jour/article/view/149

  18. 18
  19. 19
  20. 20